Evidence map›Paper›PMID 42248850›Full record

ArticleCell death & disease2026

Zfand5 terminates TLR3/4 signaling and necroptosis by targeting TRIF to the proteasome for degradation.

Wei-Ting Liao, Chia-Hsing Shen, Viriya Adhiguna Winarso, Yu-You Chen, Ke-Hsin Chen, Chun-Hsiang Chuang, En-Yi Liu, Miao-Hsien Wu, Chia-I Lien, Yu-Ching Chen and 4 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wei-Ting Liao *Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Chia-Hsing Shen *Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Viriya Adhiguna Winarso *Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Yu-You ChenGraduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Ke-Hsin ChenInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Chun-Hsiang ChuangInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
En-Yi LiuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Miao-Hsien WuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Chia-I LienInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Yu-Ching ChenInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Ting-Yu LaiInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Tsung-Hsien ChuangCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, ROC.
Chih-Yuan LeeInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.ORCID http://orcid.org/0000-0001-5034-3544
Li-Chung HsuInstitute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC. lichunghsu@ntu.edu.tw.ORCID http://orcid.org/0000-0001-7206-5231

Funding

National Taiwan University (NTU) 112-L2001National Taiwan University (NTU) NTU-CC-114L894103
6 · The paper itself

Abstract

Toll-like receptors (TLRs) are central to host defense and tissue repair, yet dysregulated TLR signaling contributes to inflammatory and autoimmune diseases. Although core TLR pathways have been defined, the mechanisms that terminate receptor signaling and restore immune homeostasis remain incompletely understood. Here, we identify the zinc finger protein Zfand5, a known proteasomal shuttling factor, as a selective negative regulator of TLR3- and TLR4-mediated inflammatory responses. Zfand5-deficient mice exhibit exacerbated sepsis and heightened cytokine production following TLR3/4 stimulation. Mechanistically, Zfand5 facilitates the proteasomal degradation of the adaptor protein TIR-domain-containing adapter-inducing interferon-β (TRIF) by bridging polyubiquitinated TRIF to the proteasome, thereby terminating downstream pro-inflammatory and type I interferon signaling. Loss of Zfand5 also enhances TRIF-dependent necroptosis upon TLR3/4 activation, further amplifying inflammation. These findings reveal an essential and previously unrecognized role for Zfand5 in regulating TRIF turnover and maintaining immune balance during innate immune responses.

Indexed as

Adaptor Proteins, Vesicular TransportNecroptosisProteasome Endopeptidase ComplexToll-Like Receptor 3Toll-Like Receptor 4AnimalsHumansImmunity, InnateInflammationMiceMice, Inbred C57BLMice, KnockoutProteolysisSignal TransductionAdaptor Proteins, Vesicular TransportProteasome Endopeptidase ComplexTicam1 protein, mouseTLR3 protein, mouseToll-Like Receptor 3Toll-Like Receptor 4

Identifiers

PMID42248850
PMCPMC13458262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.